A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women

Date Added
April 26th, 2022
PRO Number
Pro00118578
Researcher
David Soper

List of Studies


Keywords
Obstetrics and Gynecology
Summary

This study is being conducted to assess the safety and efficacy of an investigational drug for the treatment of vasomotor symptoms related to menopause. Subjects must be post menopausal, with symptoms to include moderate to sever hot flashes.

Institution
MUSC
Recruitment Contact
Jesslyn Payne
843-792-7525
paynej@musc.edu



-- OR --